



Han Zhu

Assistant Professor of Medicine (Cardiovascular Medicine)
Medicine - Cardiovascular Medicine

CLINICAL OFFICE (PRIMARY)

- **Stanford Health Care Cardiovascular Medicine**
870 Quarry Rd Rm CV2C83
Stanford, CA 94305
Tel (650) 736-1319 **Fax** (650) 725-1599

ACADEMIC CONTACT INFORMATION

- **Non-Clinical Administrative Assistant**
Angela Valdez - Admin Associate II
Email valdez23@stanford.edu
Tel 650-724-5083

Bio

BIO

Dr. Zhu is an Assistant Professor of Medicine whose clinical and research expertise focuses on cardio-oncology and cardio-immunology. She specializes in the cardiovascular care of patients undergoing therapies for cancer, with a particular focus on the effects of immunotherapies on the heart. She received a bioengineering degree from MIT, medical degree from Case Western Reserve University, and completed clinical cardiology fellowship and internal medicine residency training at Stanford University School of Medicine. Dr. Zhu's laboratory focuses on myocarditis, cardiac inflammation, and the effects of cancer therapeutics on the cardiovascular system. Her current research employs clinical data, bio-banked samples, and in vivo/in vitro preclinical models in combination with single-cell technologies to study immune-based toxicities in the heart. Dr. Zhu's clinic sees cardio-oncology and cardio-immunology patients and her lab focuses on devising new methods for minimizing cardiovascular complications in the cancer and autoimmune patient populations.

CLINICAL FOCUS

- Cardiovascular Disease
- Cardio-Oncology
- Cardio-Immunology

ACADEMIC APPOINTMENTS

- Assistant Professor - University Medical Line, Medicine - Cardiovascular Medicine
- Member, Bio-X
- Member, Cardiovascular Institute

ADMINISTRATIVE APPOINTMENTS

- Director, Stanford Translational Cardio-Oncology, (2022- present)

HONORS AND AWARDS

- NIH R01 Award, National Institutes of Health (9/2025-)
- NIH R03 Award, National Institutes of Health (8/1/2024-)

- NIH Katz R01 Award, National Institutes of Health (8/1/2024-)
- Stanford Cardiovascular Institute (CVI) Seed Grant, Stanford Cardiovascular Institute (CVI) (9/2023)
- Stanford Cardiovascular Institute (CVI) Manuscript Award, Stanford Cardiovascular Institute (CVI) (1/2023)
- NIH K08 Mentored Clinical Scientist Research Career Development Award, National Institute of Health (NIH) (2022-)
- Melvin L. Marcus Early Career Investigator Award Finalist, American Heart Association (AHA) - Basic Cardiovascular Sciences (BCVS) (2021)
- Gerald Reaven Basic Science Research Award, Stanford University (2020)
- Sarnoff Scholar Career Development Award, Sarnoff Cardiovascular Foundation (2020)
- Sanofi Innovation Awards (iAwards), Sanofi (2019-2021)
- NIH F32 Ruth Kirschstein National Research Service Award Grant, National Institute of Health (NIH) (2019)
- Stanford Cancer Institute (SCI) Innovation Award, Stanford Cancer Institute (SCI) (2019)
- NIH Loan Repayment Award, National Institute of Health (NIH) (7/2019)
- Alpha Omega Alpha (AOA) Member, Alpha Omega Alpha (AOA) (2014)
- Myron F. Kanter and Lawrence J. Kanter Endowment Fund Award, Myron F. Kanter and Lawrence J. Kanter Foundation (2014)
- Sarnoff Cardiovascular Research Foundation Fellowship, Sarnoff Cardiovascular Foundation (2012-2013)
- Irwin H. Lepow Research Award, Irwin H. Lepow Research Foundation (2011)
- American Federation of Aging Research (AFAR) Grant Recipient, American Federation of Aging Research (AFAR) (2010)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Committee Member, AHA Cardio-Oncology Subcommittee (2020 - present)
- Chair Elect, AHA Basic Cardiovascular Sciences (BCVS) Committee on Inflammation and Heart Failure (2024 - present)
- Assistant Editor, JACC: CardioOncology (2020 - present)
- Cardio-Oncology Subcommittee Member, American Heart Association (AHA) (2019 - present)
- Committee Member, American College of Cardiology Cardio-Oncology - California Chapter (2020 - present)
- Member, Society of Cardiovascular Computed Tomography (SCCT) (2019 - present)
- Member, American Society of Echocardiography (2019 - present)

PROFESSIONAL EDUCATION

- Board Certification: Adult Echocardiography, National Board of Echocardiography (2019)
- Board Certification: Cardiovascular Disease, American Board of Internal Medicine (2020)
- Board Certification, American College of Cardiology/ABIM , Cardiovascular Disease (2020)
- Fellowship: Stanford University Cardiovascular Medicine Fellowship (2020) CA
- Board Certification, Society of Cardiovascular Computer Tomography (SCCT) , Cardiac CT (2019)
- Board Certification: Internal Medicine, American Board of Internal Medicine (2017)
- Residency: Stanford University Internal Medicine Residency (2017) CA
- Medical Education: Case Western Reserve School of Medicine (2014) OH
- Residency, Stanford University , Internal Medicine (2017)
- Doctor of Medicine, Case Western Reserve University School of Medicine , Medicine (2014)
- Sarnoff Fellow, Sarnoff Cardiovascular Research Foundation , Research fellowship (2012)
- Bachelor of Science, Massachusetts Institute of Technology (MIT) , Biological Engineering (2009)

PATENTS

- Sean Wu, Han Zhu, Patricia Nguyen. "United States Patent 63/235,580 IDENTIFICATION OF PATHOGENIC IMMUNE CELL SUBSETS IN CHECKPOINT INHIBITOR-INDUCED MYOCARDITIS", Leland Stanford Junior University, Aug 20, 2021

LINKS

- Han Zhu Lab Website: <https://www.hanzhulab.com/>
- Get a Second Opinion: <https://stanfordhealthcare.org/second-opinion/overview.html>

Research & Scholarship

CLINICAL TRIALS

- IPF/ILD-PRO, Not Specified

Teaching

STANFORD ADVISEES

Med Scholar Project Advisor

Rania Abdusamad

Postdoctoral Faculty Sponsor

Min Kyung Lee, Yin Sun, Maria Rosaria Vitale

Publications

PUBLICATIONS

- **REPLY: Pragmatic Troponin Surveillance for ICI Cardiotoxicity: Impactful Lessons From Real-World Practice.** *JACC. CardioOncology*
Cheng, E., Ivanovic, M., Witteles, R., Waliany, S., Zhu, H.
2026; 8 (1): 96-97
- **Using plasma cell-free mRNA to profile immune response and myocardial damage in immune checkpoint inhibitor-induced myocarditis.** *The Journal of clinical investigation*
Raissadati, A., Zhou, X., Chou, H., Huang, Y. V., Khatua, S., Sun, Y., Xu, A., Loa, S., Hernandez, A., Zhu, H., Wu, S. M.
2025; 135 (16)
- **Cardiac Troponin Screening and Clinical Outcomes in Patients Receiving Immunotherapy.** *JACC. CardioOncology*
Cheng, E., Ivanovic, M., Chan, A., Xu, S., Franquiz, M., Lee, C., You, J., Fazal, M., Le Guen, Y., Batchelder, R., Reddy, S. A., Katsumoto, T., Ramchandran, et al
2025
- **Immune checkpoint inhibitor-associated myocarditis: a novel risk score.** *European heart journal*
Power, J. R., Dolladille, C., Ozbay, B., Procureur, A., Ederhy, S., Palaskas, N. L., Lehmann, L. H., Cautela, J., Courand, P. Y., Hayek, S. S., Zhu, H., Zaha, V. G., Cheng, et al
2025
- **Artificial Intelligence to Enhance Precision Medicine in Cardio-Oncology: A Scientific Statement From the American Heart Association** *CIRCULATION-GENOMIC AND PRECISION MEDICINE*
Khera, R., Asnani, A. H., Krive, J., Addison, D., Zhu, H., Vasbinder, A., Fleming, M. R., Arnaout, R., Razavi, P., Okwuosa, T. M., Amer Heart Assoc Cardio Oncology Data Sci Precision Med Comm Council, Council Cardiovasc Radiology Intervention, Council Cardiovasc Stroke Nursing
2025; 18 (2): e000097
- **Novel Therapeutic Approach Targeting CXCR3 to Treat Immunotherapy Myocarditis.** *Circulation research*
Huang, Y. V., Sun, Y., Chou, H., Wagner, N., Vitale, M. R., Bayer, A. L., Xu, B., Lee, D., Lin, Z., Branche, C., Waliany, S., Neal, J. W., Wakelee, et al
2025

- **Classes of Antineoplastic Agents Associated with Increased Risk of Cancer Therapy-associated Hypertension and Management Strategies.** *Cardiology clinics*
Sayegh, H., Zagouras, A., Neal, J. W., Witteles, R. M., Zhu, H., Waliany, S.
2025; 43 (1): 31-42
- **Immune Checkpoint Inhibitor Myocarditis and Left Ventricular Systolic Dysfunction** *JACC: CardioOncology*
Chen, Y., Dolladille, C., Rao, A., Palaskas, N. L., Deswal, A., Lehmann, L., Cautela, J., Courand, P., Hayek, S., Zhu, H., et al
2025; 7 (3)
- **Immune checkpoints in cardiac physiology and pathology: therapeutic targets for heart failure.** *Nature reviews. Cardiology*
Gergely, T. G., Drobni, Z. D., Kallikourdis, M., Zhu, H., Meijers, W. C., Neilan, T. G., Rassaf, T., Ferdinandy, P., Varga, Z. V.
2024
- **Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis (vol 29, pg 3100, 2023)** *NATURE MEDICINE*
Fenioux, C., Abbar, B., Boussouar, S., Bretagne, M., Power, J. R., Moslehi, J. J., Gougis, P., Amelin, D., Dechartres, A., Lehmann, L. H., Courand, P., Cautela, J., Alexandre, et al
2024
- **THE IMPACT OF ROUTINE CARDIAC TROPONIN I-BASED CARDIOTOXICITY SCREENING ON CLINICAL OUTCOMES IN PATIENTS ON CANCER IMMUNOTHERAPY** *bioRxiv*
Ivanovic, M., Chan, A., Cheng, E., Xu, S., Lee, C., Franquiz, M., You, J., Fazal, M., Batchelder, R., Reddy, S., Katsumoto, T., Ramchandran, K., Colevas, et al
2024
- **Immunotherapy-Associated Atherosclerosis: A Comprehensive Review of Recent Findings and Implications for Future Research.** *Current treatment options in cardiovascular medicine*
Chan, A., Torelli, S., Cheng, E., Batchelder, R., Waliany, S., Neal, J., Witteles, R., Nguyen, P., Cheng, P., Zhu, H.
2023; 25 (12): 715-735
- **Osimertinib-Associated Cardiomyopathy In Patients With Non-Small Cell Lung Cancer: A Case Series** *JACC: CardioOncology*
Franquiz, M., Waliany, S., Xu, A., Hnatiuk, A., Wu, S., Cheng, P., Wakelee, H., Neal, J., Witteles, R., Zhu, H.
2023: 839-841
- **Cardiomuscular Biomarkers in the Diagnosis and Prognostication of Immune Checkpoint Inhibitor Myocarditis.** *Circulation*
Lehmann, L. H., Heckmann, M. B., Bailly, G., Finke, D., Procureur, A., Power, J. R., Stein, F., Bretagne, M., Ederhy, S., Fenioux, C., Hamwy, O., Funck-Brentano, E., Romano, et al
2023
- **The potential of auto-antigen-guided treatment of immune checkpoint inhibitor-mediated myocarditis.** *Med (New York, N.Y.)*
Zhu, H., Huang, Y. V., Wu, S. M.
2023; 4 (1): 13-14
- **Late-Onset Immunotherapy-Induced Myocarditis 2 Years After Checkpoint Inhibitor Initiation.** *JACC. CardioOncology*
Nguyen, A. T., Berry, G. J., Witteles, R. M., Le, D. T., Wu, S. M., Fisher, G. A., Zhu, H.
2022; 4 (5): 727-730
- **The Role of Single-Cell Profiling and Deep Immunophenotyping in Understanding Immune Therapy Cardiotoxicity.** *JACC. CardioOncology*
Huang, Y. V., Waliany, S., Lee, D., Galdos, F. X., Witteles, R. M., Neal, J. W., Fan, A. C., Maecker, H. T., Nguyen, P. K., Wu, S. M., Zhu, H.
2022; 4 (5): 629-634
- **devCellPy is a machine learning-enabled pipeline for automated annotation of complex multilayered single-cell transcriptomic data.** *Nature communications*
Galdos, F. X., Xu, S., Goodyer, W. R., Duan, L., Huang, Y. V., Lee, S., Zhu, H., Lee, C., Wei, N., Lee, D., Wu, S. M.
2022; 13 (1): 5271
- **Coronary artery disease and revascularization associated with immune checkpoint blocker myocarditis: Report from an international registry.** *European journal of cancer (Oxford, England : 1990)*
Nowatzke, J., Guedeney, P., Palaskas, N., Lehmann, L., Ederhy, S., Zhu, H., Cautela, J., Francis, S., Courand, P. Y., Deswal, A., Ewer, S. M., Aras, M., Arangalage, et al
2022

- **Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor-Induced Myocarditis.** *Circulation*
Zhu, H., Galdos, F. X., Lee, D., Waliyany, S., Vivian Huang, Y., Ryan, J., Dang, K., Neal, J. W., Wakelee, H. A., Reddy, S. A., Srinivas, S., Lin, L. L., Witteles, et al
2022: 101161CIRCULATIONAHA121056730
- **Mono- and Biallelic Protein-Truncating Variants in Alpha-Actinin 2 Cause Cardiomyopathy Through Distinct Mechanisms.** *Circulation. Genomic and precision medicine*
Lindholm, M. E., Jimenez-Morales, D., Zhu, H., Seo, K., Amar, D., Zhao, C., Raja, A., Madhvani, R., Abramowitz, S., Espenel, C., Sutton, S., Caleshu, C., Berry, et al
2021: CIRCGEN121003419
- **Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic non-small cell lung carcinoma.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
Waliyany, S., Zhu, H., Wakelee, H., Padda, S. K., Das, M., Ramchandran, K., Myall, N. J., Chen, T., Witteles, R. M., Neal, J. W.
2021
- **Myocarditis Surveillance with High-Sensitivity Troponin I During Cancer Treatment with Immune Checkpoint Inhibitors.** *JACC. CardioOncology*
Waliyany, S., Neal, J. W., Reddy, S., Wakelee, H., Shah, S. A., Srinivas, S., Padda, S. K., Fan, A. C., Colevas, A. D., Wu, S. M., Witteles, R. M., Zhu, H.
2021; 3 (1): 137–39
- **Preclinical Models of Cancer Therapy-Associated Cardiovascular Toxicity: A Scientific Statement From the American Heart Association.** *Circulation research*
Asnani, A. n., Moslehi, J. J., Adhikari, B. B., Baik, A. H., Beyer, A. M., de Boer, R. A., Ghigo, A. n., Grumbach, I. M., Jain, S. n., Zhu, H. n.
2021: RES0000000000000473
- **Immune checkpoint inhibitor cardiotoxicity: Breaking barriers in the cardiovascular immune landscape.** *Journal of molecular and cellular cardiology*
Zhu, H., Ivanovic, M., Nguyen, A., Nguyen, P. K., Wu, S. M.
2021
- **Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response** *Curr Cardiol Rep*
Zhu, H., Rhee, J., Cheng, P., Waliyany, S., Chang, A., Witteles, R. M., Maecker, H., Davis, M. M., Nguyen, P. K., Wu, S. M.
2020; 22 (5)
- **Sinoatrial node toxicity after stereotactic ablative radiation therapy to lung tumors.** *Practical radiation oncology*
Qian, Y. n., Zhu, H. n., Pollom, E. L., Durkee, B. Y., Chaudhuri, A. A., Gensheimer, M. F., Diehn, M. n., Shultz, D. B., Loo, B. W.
2017
- **Glucocorticoids enhance muscle endurance and ameliorate Duchenne muscular dystrophy through a defined metabolic program.** *Proceedings of the National Academy of Sciences of the United States of America*
Morrison-Nozik, A., Anand, P., Zhu, H., Duan, Q., Sabeh, M., Prosdocimo, D. A., Lemieux, M. E., Nordsborg, N., Russell, A. P., MacRae, C. A., Gerber, A. N., Jain, M. K., Haldar, et al
2015; 112 (49): E6780-9
- **miR-222 is necessary for exercise-induced cardiac growth and protects against pathological cardiac remodeling.** *Cell metabolism*
Liu, X., Xiao, J., Zhu, H., Wei, X., Platt, C., Damilano, F., Xiao, C., Bezzerides, V., Boström, P., Che, L., Zhang, C., Spiegelman, B. M., Rosenzweig, et al
2015; 21 (4): 584-95
- **Kruppel-like factor 15 is a critical regulator of cardiac lipid metabolism.** *The Journal of biological chemistry*
Prosdocimo, D. A., Anand, P., Liao, X., Zhu, H., Shelkay, S., Artero-Calderon, P., Zhang, L., Kirsh, J., Moore, D., Rosca, M. G., Vazquez, E., Kerner, J., Akat, et al
2014; 289 (9): 5914-24
- **Kruppel-like factor 15 regulates skeletal muscle lipid flux and exercise adaptation.** *Proceedings of the National Academy of Sciences of the United States of America*
Haldar, S. M., Jeyaraj, D., Anand, P., Zhu, H., Lu, Y., Prosdocimo, D. A., Eapen, B., Kawanami, D., Okutsu, M., Brotto, L., Fujioka, H., Kerner, J., Rosca, et al
2012; 109 (17): 6739-44

- **Elevated fibroblast growth factor-2 increases tumor necrosis factor-alpha induced endothelial cell death in high glucose.** *Journal of cellular physiology*
Clyne, A. M., Zhu, H., Edelman, E. R.
2008; 217 (1): 86-92
- **A porous photocurable elastomer for cell encapsulation and culture.** *Biomaterials*
Gerecht, S., Townsend, S. A., Pressler, H., Zhu, H., Nijst, C. L., Bruggeman, J. P., Nichol, J. W., Langer, R.
2007; 28 (32): 4826-35
- **COMBINATION IMMUNE CHECKPOINT INHIBITOR MYOCARDITIS MANIFESTING WITH COMPLETE HEART BLOCK**
Tsai, N., Zheng, J., Zhu, H., Pizula, J.
ELSEVIER SCIENCE INC.2026: A1286
- **PRIOR MYOCARDIAL INJURY AND CLINICAL OUTCOMES IN PATIENTS WITH ICI-ASSOCIATED MYOCARDITIS**
Li, J., Khatua, S., Sun, Y., Cheng, E., Zhu, H.
ELSEVIER SCIENCE INC.2026: A1106
- **REFRACTORY IMMUNE CHECKPOINT INHIBITOR MYOCARDITIS SUCCESSFULLY TREATED WITH METHOTREXATE**
Li, J., Katsumoto, T., Zhu, H.
ELSEVIER SCIENCE INC.2026: A1502
- **Seasons of risk: Investigating temporal trends in ICI-associated Myocarditis**
Griffith, C., Park, E., Cheng, E., Mccroskey, S., Katsumoto, T., Zhu, H., Funchain, P.
AMER ASSOC CANCER RESEARCH.2026
- **Prior Myocardial Injury and Clinical Outcomes in Patients with ICI-Associated Myocarditis** *American College of Cardiology Annual Scientific Session*
Li, J., Khatua, S., Vitale, M. R., Sun, Y., Sundar, H., Elorbany, R., Cheng, E., Zhu, H.
2026
- **Combination Immune Checkpoint Inhibitor Myocarditis Manifesting with Complete Heart Block** *American College of Cardiology Annual Scientific Session*
Tsai, N., Zheng, J., Zhu, H., Pizula, J.
2026
- **Refractory Immune Checkpoint Inhibitor Myocarditis Successfully Treated with Methotrexate** *American College of Cardiology Annual Scientific Session*
Li, J., Funchain, P., Katsumoto, T., Zhu, H.
2026
- ** <u>Uncovering the Role of T-Cell and Fibroblast Crosstalk in Immunotherapy-Induced Myocarditis</u>**
Wagner, N., Vitale, M., Sun, Y., Zambrano, M., Bayer, A., Alcaide, P., Moslehi, J., Zhu, H.
LIPPINCOTT WILLIAMS & WILKINS.2025
- **Immune Checkpoint Inhibitor Myocarditis and Left Ventricular Systolic Dysfunction.** *JACC. CardioOncology*
Chen, Y. C., Dolladille, C., Rao, A., Palaskas, N. L., Deswal, A., Lehmann, L., Cautela, J., Courand, P. Y., Hayek, S., Zhu, H., Cheng, R. K., Alexandre, J., Baldassarre, et al
2025; 7 (3): 234-248
- **PO-02-141 ATRIAL FIBRILLATION IN PATIENTS ON BRUTON'S TYROSINE KINASE INHIBITORS: RISK PROFILE OF NEWER GENERATION MEDICATIONS** *Heart Rhythm*
Devathu, R., Fazal, M., Godinez, E., Albayrak, Y., Gonzalez, D., Paranjpe, I., Sun, E., Clopton, P., Wei, C., Narezkina, A., Heyman, B., Fakhri, B., Cheng, et al
2025; 22 (4): S297
- **Investigating Th17.1 Cell Recruitment and CXCR3 Blockade in the Pathogenesis of Cardiac Sarcoidosis** *REACH Capstone*
Parilla-Garcia, J., Vitale, M. R., Chou, H., Banga, N., Baker, M., Witteles, R., Zhu, H.
2025
- **Uncovering the Role of T-Cell and Fibroblast Crosstalk in Immunotherapy-Induced Myocarditis** *Circulation*
Wagner, N., Vitale, M. R., Sun, Y., Zambrano, M., Bayer, A., Alcaide, P., Moslehi, J., Zhu, H.

2025; 152 (Suppl_3): A4369397-A4369397

- **Clinical Relevance and Mechanistic Underpinnings of Tyrosine Kinase Inhibitor Associated Cardiotoxicities** *CURRENT TREATMENT OPTIONS IN CARDIOVASCULAR MEDICINE*
Torelli, S., Agnihotri, V., Zhu, H., Wang, Z., Cheng, P., Rhee, J.
2024; 27 (1)
- **Predictors and Risk Score for Immune Checkpoint-Inhibitor-Associated Myocarditis Severity.** *medRxiv : the preprint server for health sciences*
Power, J. R., Dolladille, C., Ozbay, B., Procureur, A. M., Ederhy, S., Palaskas, N. L., Lehmann, L. H., Cautela, J., Courand, P. Y., Hayek, S. S., Zhu, H., Zaha, V. G., Cheng, et al
2024
- **A Novel Therapeutic Approach using CXCR3 Blockade to Treat Immune Checkpoint Inhibitor-mediated Myocarditis** *bioRxiv*
Huang, Y. V., Lee, D., Sun, Y., Chou, H., Xu, B., Lin, Z., Branche, C., Bayer, A. L., Waliyany, S., Neal, J., Wakelee, H., Witteles, R. M., Nguyen, et al
2024
- **Clinical Risk Stratification and Immunophenotyping of Immune Checkpoint Inhibitor Associated Heart Failure with Reduced Ejection Fraction** *Bio-X Symposium*
Branche, C., Cheng, E., Huang, V., Chou, H., Zhu, H.
2024
- **Immune checkpoints in cardiac physiology and pathology: therapeutic targets for heart failure** *Nature Reviews Cardiology*
Gergely, T., Drobni, Z. D., Kallikourdis, M., Zhu, H., Meijers, W. C., Neilan, T. G., Rassaf, T., Ferdinandy, P., Varga, Z. V.
2024
- **Immune checkpoints in cardiac physiology and pathology: therapeutic targets for heart failure** *Nature Reviews Cardiology*
Gergely, T., Drobni, Z. D., Kallikourdis, M., Zhu, H., Meijers, W. C., Neilan, T. G., Rassaf, T., Ferdinandy, P., Varga, Z. V.
2024
- **miR-222 inhibits pathological cardiac hypertrophy and heart failure.** *Cardiovascular research*
Liu, X., Li, H., Hastings, M. H., Xiao, C., Damilano, F., Platt, C., Lerchenmüller, C., Zhu, H., Wei, X. P., Yeri, A., Most, P., Rosenzweig, A.
2023
- **Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis.** *Nature medicine*
Fenioux, C., Abbar, B., Boussouar, S., Bretagne, M., Power, J. R., Moslehi, J. J., Gougis, P., Amelin, D., Dechartres, A., Lehmann, L. H., Courand, P. Y., Cautela, J., Alexandre, et al
2023; 29 (12): 3100-3110
- **Impact of Troponin Monitoring on Cardiac Outcomes in Patients Receiving Immune Checkpoint Inhibitors**
Ivanovic, M., Chan, A., Franquiz, M., Xu, S., Lee, C., Fazal, M., You, J., Witteles, R., Neal, J., Wu, S., Waliyany, S., Zhu, H.
WILEY.2023: 2087-2089
- **OSIMERTINIB-ASSOCIATED CARDIOMYOPATHY: A RETROSPECTIVE ANALYSIS OF THE STANFORD NON-SMALL CELL LUNG CANCER PATIENT COHORT**
Franquiz, M., Witteles, R., Zhu, H., Waliyany, S.
ELSEVIER SCIENCE INC.2023: 411
- **ACUTE CARDIOMYOPATHY AFTER INITIATION OF CABOZANTINIB, A MULTITYROSINE KINASE INHIBITOR**
Cheng, E., Zhu, H.
ELSEVIER SCIENCE INC.2023: 2670
- **Pharmacovigilance Analysis of Heart Failure Associated With Anti-HER2 Monotherapies and Combination Regimens for Cancer.** *JACC. CardioOncology*
Waliyany, S., Caswell-Jin, J., Riaz, F., Myall, N., Zhu, H., Witteles, R. M., Neal, J. W.
2023; 5 (1): 85-98
- **Immunotherapy-Associated Atherosclerosis: A Comprehensive Review of Recent Findings and Implications for Future Research** *Current Treatment Options in Cardiovascular Medicine*
Chan, A., Torelli, S., Cheng, E., Batchelder, R., Waliyany, S., Neal, J., Witteles, R., Nguyen, P., Cheng, P., Zhu, H.
2023

- **Identification of an in vivo cardiomyocyte-T-cell co-culture model for the development of cardiac anti-inflammatory drugs** *Stanford-Upenn-Duke-Cornell Symposium*
Sun, Y., Huang, Y. V., Chou, H., Lin, Z., Zhu, H.
2023
- **Deep Immunophenotyping of Patients with Cardiac Sarcoidosis Using Single-Cell Multi-Omics** *Stanford Upenn Duke Cornell Symposium*
Chou, H., Huang, Y., Banga, N., Maecker, H., Baker, M., Witteles, R., Zhu, H.
2023
- **Developing a Human Monocyte Derived Macrophage Phenotyping Pipeline to Study Immunogenic Effects of Cardiac Troponin I** *Stanford Duke Cornell Upenn Symposium*
Lin, Z., Sun, Y., Huang, Y. V., Chou, H., Wu, S., Maecker, H., Blish, C., Rustagi, A., Mochly-Rosen, D., Elezaby, A., Zhu, H.
2023
- **Impact of Troponin Monitoring on Cardiac Outcomes in Patients Receiving Immune Checkpoint Inhibitors** *Arthritis Rheumatology*
Ivanovic, M., Chan, A., Franquiz, M., Xu, S., Lee, C., Muhammad, F., You, J., Witteles, R., Neal, J., Wu, S., Waliany, S., Zhu, H.
2023; 73
- **Pharmacovigilance Analysis of Heart Failure Associated With Anti-HER2 Monotherapies and Combination Regimens for Cancer** *Jacc: CardioOncology*
Waliany, S., Caswell-Jin, J., Riaz, F., Myall, N., Zhu, H., Witteles, R. M., Neal, J. W.
2023; 5 (1): 85-98
- **Late-Onset Immunotherapy-Induced Myocarditis 2 Years After Checkpoint Inhibitor Initiation** *JACC: CardioOncology*
Nguyen, A. T., Berry, G. J., Witteles, R. M., Le, D. T., Wu, S. M., Fisher, G. A., Zhu, H.
2022; 4 (5): 727-730
- **Plasma exchange for severe immune-related adverse events from checkpoint inhibitors: an early window of opportunity?** *Immunotherapy advances*
Katsumoto, T. R., Wilson, K. L., Giri, V. K., Zhu, H., Anand, S., Ramchandran, K. J., Martin, B. A., Yunce, M., Muppidi, S.
2022; 2 (1): Itac012
- **LATE ONSET IMMUNOTHERAPY-INDUCED MYOCARDITIS TWO YEARS AFTER CHECKPOINT INHIBITOR INITIATION**
Nguyen, A. T., Witteles, R. M., Zhu, H.
2022: S8-S9
- **The Role of Single-Cell Profiling and Deep Immunophenotyping in Understanding Immune Therapy Cardiotoxicity** *JACC: CardioOncology*
Huang, Y. V., Waliany, S., Lee, D., Galdos, F. X., Witteles, R. M., Neal, J. W., Fan, A. C., Maecker, H. T., Nguyen, P. K., Wu, S. M., Zhu, H.
2022; 4 (5): 629-634
- **Immune Profiling and Causal Antigen Discovery in Mouse and Human Models of Immune Checkpoint Inhibitor-induced Myocarditis**
Zhu, H., Lee, D., Sarah, W., Galdos, F. X., D'Addabbo, J., Fowler, M. B., Reddy, S., Heather, W., Neal, J. W., Witteles, R., Maecker, H. T., Davis, M., Nguyen, et al
LIPPINCOTT WILLIAMS & WILKINS.2020
- **Correction to: Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response.** *Current cardiology reports*
Zhu, H., Rhee, J., Cheng, P., Waliany, S., Chang, A., Witteles, R. M., Maecker, H., Davis, M. M., Nguyen, P. K., Wu, S. M.
2020; 22 (5): 36
- **Immune Profiling and Causal Antigen Discovery in Mouse and Human Models of Immune Checkpoint Inhibitor-induced Myocarditis** *Basic Cardiovascular Sciences (BCVS) Scientific Sessions*
Zhu, H., Lee, D., Waliany, S., Galdos, F., D'Addabbo, J., Fowler, M. B., Reddy, S., Wakelee, H., Neal, J. W., Witteles, R. M., Maecker, H. T., Davis, M. M., Nguyen, et al
2020
- **Cardiovascular Risks in Patients with COVID-19: Potential Mechanisms and Areas of Uncertainty.** *Current cardiology reports*
Cheng, P. n., Zhu, H. n., Witteles, R. M., Wu, J. C., Quertermous, T. n., Wu, S. M., Rhee, J. W.
2020; 22 (5): 34

- **Low Wall Shear Stress Is Associated with Saphenous Vein Graft Stenosis in Patients with Coronary Artery Bypass Grafting.** *Journal of cardiovascular translational research*
Khan, M. O., Tran, J. S., Zhu, H. n., Boyd, J. n., Packard, R. R., Karlsberg, R. P., Kahn, A. M., Marsden, A. L.
2020
- **Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure.** *Annual review of pharmacology and toxicology*
Waliany, S. n., Lee, D. n., Witteles, R. M., Neal, J. W., Nguyen, P. n., Davis, M. M., Salem, J. E., Wu, S. M., Moslehi, J. J., Zhu, H. n.
2020
- **A Case of Early Immune Checkpoint Inhibitor Myocarditis Detected on Routine Troponin Monitoring** *Advancing the Cardiovascular Care of the Oncology Patient*
Zhu, H., Waliany, S., Neal, J., Wakelee, H., Wu, S. M., Witteles, R. M.
2020
- **NOVEL ALPHA-ACTININ 2 MUTATIONS ARE ASSOCIATED WITH CARDIOMYOPATHY AND HYPERTROPHY IN HUMAN CARDIAC TISSUE AND IPSC-DERIVED CARDIOMYOCYTES**
Lindholm, M., Zhu, H., Huang, Y., Ashley, E. A., Wheeler, M.
ELSEVIER SCIENCE INC.2019: 1027
- **Computational Fluid Dynamics of CABG Patients: CTA-derived Hemodynamic and Anatomic Predictors of Vein Graft Failure.** *Society of Cardiovascular Computed Tomography.*
Kahn, M., Tran, J., Zhu, H., Packard, R., Karlsberg, R., Marsden, A.
2019
- **Computational Fluid Dynamics (BypassCFD) Trumps Anatomic Predictors of Saphenous Vein Graft Failure in CABG Patients**
Khan, M., Tran, J. S., Zhu, H., Packard, R. S., Karlsberg, R. P., Kahn, A., Marsden, A. L.
LIPPINCOTT WILLIAMS & WILKINS.2018
- **Computational Fluid Dynamics (BypassCFD) Trumps Anatomic Predictors of Saphenous Vein Graft Failure in CABG Patients** *American Heart Association*
Kahn, O., Tran, J. S., Zhu, H., Packard, R. S., Karlsberg, R. P., Kahn, A., Marsden, A.
2018
- **ACTN2 Mutations Are Associated With Cardiomyopathy and Cardiomyocyte Hypertrophy**
Zhu, H., Ashley, E., Wheeler, M.
LIPPINCOTT WILLIAMS & WILKINS.2016
- **Characterization of Actin as a Cofactor for the Adenovirus Proteinase.** *Annual Research Exhibition at Brookhaven National Lab.*
Zhu, H., McGrat, W., Walter, M.
2007